In this episode, Ryan D. Gentzler, MD, MS, and Jonathan Riess, MD, MS, answer audience questions on managing EGFR-mutated non-small-cell lung cancer (NSCLC) from a live meeting series. The episode includes expert insights on:

• Identifying patients who may benefit the most from adjuvant osimertinib  

• Testing for EGFR mutations in early-stage NSCLC

• Critical importance of getting molecular test results before starting immunotherapy

• Monitoring cardiac toxicity in patients receiving osimertinib

• Key ongoing trials in EGFR-mutated NSCLC for patients with newly diagnosed disease and following progression on osimertinib

Presenters:

Ryan D. Gentzler, MD, MS
Associate Professor
Division of Hematology/Oncology
Department of Medicine
University of Virginia
Thoracic Medical Oncologist
University of Virginia Comprehensive Cancer Center
Charlottesville, Virginia

Jonathan Riess, MD, MS
Associate Professor
Department of Internal Medicine/Hematology-Oncology
University of California, Davis
Medical Director, Thoracic Oncology
University of California, Davis Comprehensive Cancer Center
Sacramento, California

Link to full program: 
https://bit.ly/3DZGzSO